Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Report of the third outcome measures in myotonic dystrophy type 1 (OMMYD-3) international workshop Paris, France, June 8, 2015.

Gagnon C, Heatwole C, Hébert LJ, Hogrel JY, Laberge L, Leone M, Meola G, Richer L, Sansone V, Kierkegaard M.

J Neuromuscul Dis. 2018 Sep 14. doi: 10.3233/JND-180329. [Epub ahead of print] No abstract available.

PMID:
30248061
2.

Patient Reported Impact of Symptoms in Spinal Muscular Atrophy (PRISM-SMA).

Mongiovi P, Dilek N, Garland C, Hunter M, Kissel JT, Luebbe E, McDermott MP, Johnson N, Heatwole C.

Neurology. 2018 Sep 25;91(13):e1206-e1214. doi: 10.1212/WNL.0000000000006241. Epub 2018 Aug 24.

PMID:
30143566
3.

The Charcot-Marie-Tooth Health Index: Evaluation of a Patient-Reported Outcome.

Johnson NE, Heatwole C, Creigh P, McDermott MP, Dilek N, Hung M, Bounsanga J, Tang W, Shy ME, Herrmann DN.

Ann Neurol. 2018 Aug;84(2):225-233. doi: 10.1002/ana.25282. Epub 2018 Aug 29.

PMID:
30014533
4.

A Qualitative Approach to Health Related Quality-of-Life in Congenital Muscular Dystrophy.

Cornwall KM, Butterfield RJ, Hernandez A, Heatwole C, Johnson NE.

J Neuromuscul Dis. 2018;5(2):251-255. doi: 10.3233/JND-170252.

PMID:
29689733
5.

Electrical impedance myography in facioscapulohumeral muscular dystrophy: A 1-year follow-up study.

Mul K, Heatwole C, Eichinger K, Dilek N, Martens WB, Van Engelen BGM, Tawil R, Statland JM.

Muscle Nerve. 2018 Aug;58(2):213-218. doi: 10.1002/mus.26127. Epub 2018 Apr 17.

PMID:
29543984
6.

Facioscapulohumeral muscular dystrophy functional composite outcome measure.

Eichinger K, Heatwole C, Iyadurai S, King W, Baker L, Heininger S, Bartlett A, Dilek N, Martens WB, Mcdermott M, Kissel JT, Tawil R, Statland JM.

Muscle Nerve. 2018 Jan 30. doi: 10.1002/mus.26088. [Epub ahead of print]

PMID:
29381807
7.

Myotonic dystrophy patient preferences in patient-reported outcome measures.

Heatwole C, Johnson N, Dekdebrun J, Dilek N, Eichinger K, Hilbert J, Luebbe E, Martens W, Mcdermott MP, Thornton C, Moxley R.

Muscle Nerve. 2018 Jan 12. doi: 10.1002/mus.26066. [Epub ahead of print]

PMID:
29328504
8.

French translation and cross-cultural adaptation of The Myotonic Dystrophy Health Index.

Gagnon C, Tremblay M, CôTé I, Heatwole C.

Muscle Nerve. 2018 Apr;57(4):686-689. doi: 10.1002/mus.25994. Epub 2017 Nov 14.

PMID:
29053894
9.

The Myotonic Dystrophy Health Index: Italian validation of a disease-specific outcome measure.

Sansone VA, Lizio A, Greco L, Gragnano G, Zanolini A, Gualandris M, Iatomasi M, Heatwole C.

Neuromuscul Disord. 2017 Nov;27(11):1047-1053. doi: 10.1016/j.nmd.2017.07.004. Epub 2017 Jul 10.

PMID:
28890289
10.

Patient-identified impact of symptoms in spinal and bulbar muscular atrophy.

Guber RD, Kokkinis AD, Schindler AB, Bendixen RM, Heatwole CR, Fischbeck KH, Grunseich C.

Muscle Nerve. 2018 Jan;57(1):40-44. doi: 10.1002/mus.25957. Epub 2017 Sep 25.

11.

Prospective measurement of quality of life in myotonic dystrophy type 1.

Peric S, Heatwole C, Durovic E, Kacar A, Nikolic A, Basta I, Marjanovic A, Stevic Z, Lavrnic D, Rakocevic Stojanovic V.

Acta Neurol Scand. 2017 Dec;136(6):694-697. doi: 10.1111/ane.12788. Epub 2017 Jun 28.

PMID:
28660733
12.

Patient-Centered Therapy Development for Myotonic Dystrophy: Report of the Myotonic Dystrophy Foundation-Sponsored Workshop.

Hesterlee S, Amur S, Bain LJ, Carulli J, Clarke S, Day JW, Gagnon C, Hagerman K, Heatwole C, Johnson NE, Moxley R 3rd, Patel N, Thornton C, Kessel W, White M.

Ther Innov Regul Sci. 2017 Jul;51(4):516-522. doi: 10.1177/2168479016683988. Epub 2017 Feb 9.

PMID:
30227044
13.

Inclusion Body Myositis: What Most Impacts Patients' Lives.

Gibson C, Johnson NE, Eastwood E, Heatwole C.

J Clin Neuromuscul Dis. 2016 Dec;18(2):67-71.

PMID:
27861218
14.

The Impact of Pregnancy on Myotonic Dystrophy: A Registry-Based Study.

Johnson NE, Hung M, Nasser E, Hagerman KA, Chen W, Ciafaloni E, Heatwole CR.

J Neuromuscul Dis. 2015 Oct 7;2(4):447-452.

15.

What Matters Most: A Perspective From Adult Spinal Muscular Atrophy Patients.

Hunter M, Heatwole C, Luebbe E, Johnson NE.

J Neuromuscul Dis. 2016 Aug 30;3(3):425-429.

PMID:
27854231
16.

Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy.

Eichinger K, Heatwole C, Heininger S, Stinson N, Matichak Stock C, Grosmann C, Wagner KR, Tawil R, Statland JM; FSHD Clinical Trials Research Network.

Muscle Nerve. 2017 Mar;55(3):333-337. doi: 10.1002/mus.25251. Epub 2016 Dec 5.

17.

Disease burden and functional outcomes in congenital myotonic dystrophy: A cross-sectional study.

Johnson NE, Butterfield R, Berggren K, Hung M, Chen W, DiBella D, Dixon M, Hayes H, Pucillo E, Bounsanga J, Heatwole C, Campbell C.

Neurology. 2016 Jul 12;87(2):160-7. doi: 10.1212/WNL.0000000000002845. Epub 2016 Jun 15.

18.

Electrical impedance myography in facioscapulohumeral muscular dystrophy.

Statland JM, Heatwole C, Eichinger K, Dilek N, Martens WB, Tawil R.

Muscle Nerve. 2016 Oct;54(4):696-701. doi: 10.1002/mus.25065. Epub 2016 May 25.

19.

Patient-Reported Impact of Symptoms in Myotonic Dystrophy Type 2 (PRISM-2).

Heatwole C, Johnson N, Bode R, Dekdebrun J, Dilek N, Hilbert JE, Luebbe E, Martens W, McDermott MP, Quinn C, Rothrock N, Thornton C, Vickrey BG, Victorson D, Moxley RT 3rd.

Neurology. 2015 Dec 15;85(24):2136-46. doi: 10.1212/WNL.0000000000002225. Epub 2015 Nov 18.

20.

Parent-reported multi-national study of the impact of congenital and childhood onset myotonic dystrophy.

Johnson NE, Ekstrom AB, Campbell C, Hung M, Adams HR, Chen W, Luebbe E, Hilbert J, Moxley RT 3rd, Heatwole CR.

Dev Med Child Neurol. 2016 Jul;58(7):698-705. doi: 10.1111/dmcn.12948. Epub 2015 Oct 28.

21.

Evidence-based guideline summary: Evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine.

Tawil R, Kissel JT, Heatwole C, Pandya S, Gronseth G, Benatar M; Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology; Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine.

Neurology. 2015 Jul 28;85(4):357-64. doi: 10.1212/WNL.0000000000001783.

22.

Myotonic dystrophy health index: Correlations with clinical tests and patient function.

Heatwole C, Bode R, Johnson NE, Dekdebrun J, Dilek N, Eichinger K, Hilbert JE, Logigian E, Luebbe E, Martens W, Mcdermott MP, Pandya S, Puwanant A, Rothrock N, Thornton C, Vickrey BG, Victorson D, Moxley RT 3rd.

Muscle Nerve. 2016 Feb;53(2):183-90. doi: 10.1002/mus.24725. Epub 2015 Dec 29.

23.

Disease course and therapeutic approach in dermatomyositis: A four-center retrospective study of 100 patients.

Johnson NE, Arnold WD, Hebert D, Gwathmey K, Dimachkie MM, Barohn RJ, McVey AL, Pasnoor M, Amato AA, McDermott MP, Kissel J, Heatwole CR.

Neuromuscul Disord. 2015 Aug;25(8):625-31. doi: 10.1016/j.nmd.2015.04.013. Epub 2015 May 7.

24.

Report of the second Outcome Measures in Myotonic Dystrophy type 1 (OMMYD-2) international workshop San Sebastian, Spain, October 16, 2013.

Gagnon C, Meola G, Hébert LJ, Laberge L, Leone M, Heatwole C.

Neuromuscul Disord. 2015 Jul;25(7):603-16. doi: 10.1016/j.nmd.2015.01.008. Epub 2015 Jan 27. No abstract available.

PMID:
25802024
25.

Measuring quality of life in muscular dystrophy.

Bann CM, Abresch RT, Biesecker B, Conway KC, Heatwole C, Peay H, Scal P, Strober J, Uzark K, Wolff J, Margolis M, Blackwell A, Street N, Montesanti A, Bolen J.

Neurology. 2015 Mar 10;84(10):1034-42. doi: 10.1212/WNL.0000000000001336. Epub 2015 Feb 6.

26.

Quality-of-life in Charcot-Marie-Tooth disease: the patient's perspective.

Johnson NE, Heatwole CR, Dilek N, Sowden J, Kirk CA, Shereff D, Shy ME, Herrmann DN; Inherited Neuropathies Consortium.

Neuromuscul Disord. 2014 Nov;24(11):1018-23. doi: 10.1016/j.nmd.2014.06.433. Epub 2014 Jun 27.

27.

Myotonic Dystrophy Health Index: initial evaluation of a disease-specific outcome measure.

Heatwole C, Bode R, Johnson N, Dekdebrun J, Dilek N, Heatwole M, Hilbert JE, Luebbe E, Martens W, Mcdermott MP, Rothrock N, Thornton C, Vickrey BG, Victorson D, Moxley R 3rd.

Muscle Nerve. 2014 Jun;49(6):906-14. doi: 10.1002/mus.24097.

28.

Patient identification of the symptomatic impact of charcot-marie-tooth disease type 1A.

Johnson NE, Heatwole CR, Ferguson M, Sowden JE, Jeanat S, Herrmann DN.

J Clin Neuromuscul Dis. 2013 Sep;15(1):19-23. doi: 10.1097/CND.0b013e31829e22e3.

29.

Splicing biomarkers of disease severity in myotonic dystrophy.

Nakamori M, Sobczak K, Puwanant A, Welle S, Eichinger K, Pandya S, Dekdebrun J, Heatwole CR, McDermott MP, Chen T, Cline M, Tawil R, Osborne RJ, Wheeler TM, Swanson MS, Moxley RT 3rd, Thornton CA.

Ann Neurol. 2013 Dec;74(6):862-72. doi: 10.1002/ana.23992.

30.

Teaching video neuroimages: trapezius myotonia percussion sign in myotonic dystrophy type 2.

Johnson NE, Heatwole CR.

Neurology. 2013 Jun 11;80(24):e251. doi: 10.1212/WNL.0b013e318296e905. No abstract available.

31.

The impact of congenital and childhood myotonic dystrophy on quality of life: a qualitative study of associated symptoms.

Johnson NE, Luebbe E, Eastwood E, Chin N, Moxley RT 3rd, Heatwole CR.

J Child Neurol. 2014 Jul;29(7):983-6. doi: 10.1177/0883073813484804. Epub 2013 Apr 22.

PMID:
23611887
32.

The diagnosis and treatment of myotonic disorders.

Heatwole CR, Statland JM, Logigian EL.

Muscle Nerve. 2013 May;47(5):632-48. doi: 10.1002/mus.23683. Epub 2013 Mar 27. Review.

PMID:
23536309
33.

Reevaluating measures of disease progression in facioscapulohumeral muscular dystrophy.

Statland JM, McDermott MP, Heatwole C, Martens WB, Pandya S, van der Kooi EL, Kissel JT, Wagner KR, Tawil R.

Neuromuscul Disord. 2013 Apr;23(4):306-12. doi: 10.1016/j.nmd.2013.01.008. Epub 2013 Feb 11.

34.

Patient-identified disease burden in facioscapulohumeral muscular dystrophy.

Johnson NE, Quinn C, Eastwood E, Tawil R, Heatwole CR.

Muscle Nerve. 2012 Dec;46(6):951-3. doi: 10.1002/mus.23529.

35.

Myotonic dystrophy: from bench to bedside.

Johnson NE, Heatwole CR.

Semin Neurol. 2012 Jul;32(3):246-54. doi: 10.1055/s-0032-1329202. Epub 2012 Nov 1. Review.

PMID:
23117949
36.

Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1).

Heatwole C, Bode R, Johnson N, Quinn C, Martens W, McDermott MP, Rothrock N, Thornton C, Vickrey B, Victorson D, Moxley R 3rd.

Neurology. 2012 Jul 24;79(4):348-57. doi: 10.1212/WNL.0b013e318260cbe6. Epub 2012 Jul 11. Erratum in: Neurology. 2012 Sep 25;79(13):1411.

37.

Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study.

Heatwole C, Johnson N, Holloway R, Noyes K.

J Clin Neuromuscul Dis. 2011 Dec;13(2):85-94. doi: 10.1097/CND.0b013e31822c34dd.

38.

Laboratory abnormalities in patients with myotonic dystrophy type 2.

Heatwole C, Johnson N, Goldberg B, Martens W, Moxley R 3rd.

Arch Neurol. 2011 Sep;68(9):1180-4. doi: 10.1001/archneurol.2011.191.

39.

Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1.

Heatwole CR, Eichinger KJ, Friedman DI, Hilbert JE, Jackson CE, Logigian EL, Martens WB, McDermott MP, Pandya SK, Quinn C, Smirnow AM, Thornton CA, Moxley RT 3rd.

Arch Neurol. 2011 Jan;68(1):37-44. doi: 10.1001/archneurol.2010.227. Epub 2010 Sep 13.

40.

Evoked myotonia can be "dialed-up" by increasing stimulus train length in myotonic dystrophy type 1.

Logigian EL, Twydell P, Dilek N, Martens WB, Quinn C, Wiegner AW, Heatwole CR, Thornton CA, Moxley RT 3rd.

Muscle Nerve. 2010 Feb;41(2):191-6. doi: 10.1002/mus.21481.

41.

Mycophenolate mofetil for myasthenia gravis: a clear and present controversy.

Heatwole C, Ciafaloni E.

Neuropsychiatr Dis Treat. 2008 Dec;4(6):1203-9.

42.

International Education Issues: practicing and teaching international neurology: the Krakow experience.

Heatwole C.

Neurology. 2007 Oct 23;69(17):1721-3. No abstract available.

PMID:
17954789
43.

The nondystrophic myotonias.

Heatwole CR, Moxley RT 3rd.

Neurotherapeutics. 2007 Apr;4(2):238-51. Review.

PMID:
17395134
44.

Laboratory abnormalities in ambulatory patients with myotonic dystrophy type 1.

Heatwole CR, Miller J, Martens B, Moxley RT 3rd.

Arch Neurol. 2006 Aug;63(8):1149-53.

PMID:
16908743
45.

Extreme spindles: a distinctive EEG pattern in Mycoplasma pneumoniae encephalitis.

Heatwole CR, Berg MJ, Henry JC, Hallman JL.

Neurology. 2005 Mar 22;64(6):1096-7. No abstract available.

PMID:
15781845

Supplemental Content

Loading ...
Support Center